Email Updates

You are here

Home

4 NOVEMBER 2022 VOLUME 24 ISSUE 44

Media Coverage

  • PrEP4All Remembers Dr. Dawn Smith, A Champion For Equity, PrEP, and HIV Prevention

    PrEP4All mourns the loss of Dr. Dawn Smith, who passed on Wednesday, November 2, 2022. Dr. Smith, a medical officer for the CDC’s Department of HIV Prevention, was a public health expert, advocate and tireless ally in the fight for health justice. Her work to make PrEP accessible to communities vulnerable to HIV saved lives and changed communities. We join with so many in the HIV community in grieving her loss and celebrating her life and contributions.

    November 4, 2022
    PrEP4All

  • Stigma and Discrimination Against People with HIV are as Big an Issue as Ever

    Preliminary results from a survey of stigma and discrimination conducted by the European Centre for Disease Prevention and Control (ECDC) show that people living with HIV in Europe are as likely to have experienced stigma in recent years as they were a decade ago.

    November 3, 2022
    aidsmap

  • PrEP: Two-thirds of people unable to access HIV prevention pill, alarming report reveals

    Almost two-thirds (65 per cent) of people are not able to readily access PrEP, according to report on the obstacles blocking access to HIV prevention care.

    November 3, 2022
    PrEP
    PinkNews

  • Proof-of-Concept Study Shows Positive Results for Novel HIV Treatment

    An investigational broadly neutralizing antibody (bNAB), N6LS (VH3810109; GSK), produced positive results in a phase 2a proof-of-concept study. The experimental treatment is being studied at 2 dosing levels—a high dose and a 10-fold lower dose—in adult patients living with HIV. The study found that a single infusion of N6LS showed strong antiviral efficacy at both dose levels and was well-tolerated by study participants.

    November 3, 2022
    Pharmacy Times

  • HIV Seroconversions Tied to Poor PrEP Adherence

    People who seroconverted were insufficiently adherent to HIV PrEP despite being at high risk for acquiring HIV, according to a recent study.

    November 3, 2022
    PrEP
    Healio

  • 2022's Most Amazing People Living With HIV

    Meet ten people living with HIV who are bettering the world by fighting for more health care, increased access to treatment, and an end to stigma.

    November 2, 2022
    Plus

  • AELIX Therapeutics Publishes Positive Data on its HIV Vaccine

    The AELIX-002 study evaluated the efficacy of a T-cell therapeutic HIV vaccine enabling a prolonged period without anti-retroviral Therapy (ART). The strength of the vaccine-induced T-cell response significantly correlated with prolonged periods off ART. The results support the development of combination strategies based on the HTI vaccine to control HIV without the need for ongoing ART.

    November 2, 2022
    Treatment
    Labiotech.eu

  • $8M Awarded to 17 Community Groups Boosting HIV Prevention for Black Women

    ViiV Healthcare awarded a total of $8 million to help 17 community-based organizations promote HIV prevention and care for Black women.

    November 1, 2022
    POZ

  • After Viral Rebound, Dolutegravir-based Treatment More Likely to Suppress HIV

    Dolutegravir-based treatment is significantly more likely to result in re-suppression of HIV after viral rebound than treatment containing efavirenz, a meta-analysis of four large clinical trials has reported.

    October 31, 2022
    aidsmap

  • New COVID Vaccine Could Be Excellent Option for People With HIV

    Results from a Phase I CORAL-BOOST and CORAL-CEPI trial under biotechnology company Gritstone Bio shows their self-amplifying mRNA (samRNA) vaccine can induce a safe, strong, and durable immune response against COVID-19. “By including immunocompromised patients in our trial, including people living with HIV, we are able to evaluate whether our vaccine candidates, which are designed to drive both neutralizing antibodies and T cells utilizing self-amplifying mRNA, could provide better immune protection than the current vaccines for this at-risk population.”

    October 31, 2022
    Plus

  • Start HIV Antiretroviral Therapy ASAP, Experts Urge

    Early initiation of antiretroviral therapy (ART) in patients with HIV can lead to better outcomes, especially for those ages 35 and younger, a follow-up analysis of the START trial showed.

    October 25, 2022
    MedPage Today

  • GSK's ViiV Gives Early Look at HIV Broadly Neutralizing Antibody's Power, Eyes Long-acting Combo Trial

    Existing HIV antiretroviral therapies are mostly small-molecule drugs that require daily medication. Broadly neutralizing antibodies (bNAbs) hold promise as potential longer-term options, and GSK’s ViiV Healthcare has provided encouraging early proof-of-concept data for such a candidate.

    October 25, 2022
    FierceBiotech

  • Personal Lubricant Made from Cow Mucus May Protect Against HIV

    In a laboratory study, human epithelial cells were treated with the lubricant before being exposed to HIV or a herpes virus, with subsequent infection rates being as low as 20 percent.

    October 14, 2022
    Lubricant, Microbicides
    New Scientist

  • CDC: Latinos with HIV report stigma, discrimination

    Latinos with HIV are facing stigma and discrimination due to their diagnosis, making it harder for them to receive adequate care, according to CDC data released Thursday.

    October 14, 2022
    Axios

Published Research

Announcements